Hemoglobin variability in patients with chronic kidney disease in the Netherlands

International Journal of Artificial Organs

Volumn 32, Issue 11, 2009, Pages 787-793

  Van Der Putten, Karien ^a   Van Der Baan, Frederieke H ^b   Schellekens, Huub ^b   Gaillard, Carlo A J M ^a,c  

^a MEANDER MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anemia; Chronic kidney failure; Erythropoietin; Hemoglobin; Western Europe

Indexed keywords

CLINICAL RESEARCH; DIALYSIS; HEMODIALYZERS; PATIENT MONITORING; PATIENT TREATMENT;

ANEMIA; CHRONIC KIDNEY FAILURE; ERYTHROPOIESIS-STIMULATING AGENTS; ERYTHROPOIETIN; HAEMODIALYSIS; HAEMOGLOBINS; HEMODIALYSIS PATIENT; NETHERLANDS; PERITONEAL DIALYSIS; WESTERN EUROPE;

HEMOGLOBIN;

ANTIANEMIC AGENT; HEMOGLOBIN;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; DRUG RESPONSE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; PERITONEAL DIALYSIS;

EID: 74049147875     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903201104     Document Type: Article

References (26)

1. Regidor DL, Kopple JD, Kovesdy C P, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-91.
2. Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 2005; 68: 1432-8.
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61.
4. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20: 345-9.
5. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
6. Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2): ii1-47.
7. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530.
8. Anemia directive based on the Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. http://www.nefro.nl
9. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-21.
10. Lacson E, Jr., Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in esrd. Am J Kidney Dis 2003; 41: 111-24.
11. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-43.
12. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with esrd: An analysis of recent us prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 481-8.
13. Ebben J P, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-10.
14. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007; 22: 2129-32.
15. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in esrd. J Am Soc Nephrol 2007; 18: 3164-70.
16. Goodkin DA, Gimenez LF, Graber SE, Van Stone JC, Egrie JC, Okamoto DM. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: A post hoc analysis. Clin Nephrol 1999; 51: 367-72.
17. Bellizzi V, Minutolo R, Terracciano V, et al. Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 2002; 40: 549-55.
18. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-5.
19. Gilbertson DT, Ebben J P, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-8.
20. Brunelli SM, Joffe MM, Israni RK, et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 777-82.
21. Spiegel DM. Hemoglobin variability in chronic kidney disease: A cross-sectional study. Am J Med Sci 2009; 337: 340-3.
22. Minutolo R, Chiodini P, Cianciaruso B, et al. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 552-9.
23. DeFrancisco AL, Macdougall IC, Carrera F, et al. Intercurrent events and comorbid conditions infuence hemoglobin level variability in dialysis patients. Clin Nephrol 2009; 71: 397-404.
24. Boudville NC, Djurdjev O, Macdougall IC, et al. Hemoglobin variability in nondialysis chronic kidney disease: Examining the association with mortality. Clin J Am Soc Nephrol 2009; 4: 1176-82.
25. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479-87.
26. Eckardt KU, Fouqueray B, Macdougall IC, on behalf of the ARO study group. Hemoglobin variability is not an independent predictor of mortality in a European haemodialysis population: Results from the ARO study. World Congress of Nephrology, Milan, 2009